Significantly lower SMAD1 expression was confirmed by reverse transcriptase quantitative PCR (RT-qPCR) analysis of a different cohort including bone marrow samples from AML patients with and without KMT2A rearrangement (Figure 1C). This evidence concerns the gene SMAD1 and acute myeloid leukemia.